Bikram Bakshi compares the pricing of ColoWatch's non-invasive virtual colonoscopy approach to conventional colonoscopies.
Insight
Bakshi: Multi-founder startups handle crises and operate more smoothly
“What I will say is that the boards that I sit on, if there are multiple founders, things tend to be a little less frantic in that when there's a moment of crisis or there is a situation which demands attention, having more than one founder As making the ultima…”
Insight
Bakshi: Founder equity dilution is less important than avoiding single points of failure
“From a, from an arithmetic standpoint, yes, it'll make an impact, but frankly, there is, there are just so many unknowns at this stage of life of a startup company that I think the weight that, that equity ownership across two or three founders carries is not …”
Insight
Bakshi: Active usage growth is the best proxy for revenue and stickiness
“There are certain industries and verticals where usage is much more important as an indicator of early success. Obviously, we'd love to see revenue and real dollars coming in, but usage and usage in a meaningful way is the best proxy you can have about how sti…”
Prediction Held up
Bakshi: Early Indications Suggest VC Exits Will Improve in 2025
“And actually we're hoping, 25 is better. We're hoping we see more exits. And in our senses, it, at least early indications are that it will be better. We are certainly cautiously optimistic.”
Prediction Not checkable as stated
Bakshi: Trump administration will likely accelerate value-based healthcare trends
“If anything, given what I know about the mindset of the people who are in the leadership, From this administration standpoint, they will probably accelerate a lot of these trends and anything that shows high value reduction in the cost of care with the same le…”
Assertion Contradicted
Bakshi: ColoWatch studies find three non-colon cancers per colon cancer detected
“For every one colon cancer, That they have found in their studies over the last 20 years, they have found three other non-colon cancers in the same study.”